Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01852136 · ClinicalTrials.gov registry record
Clinical Evaluation of BD NEXT Pen Needle
A clinical trial, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 217
- Enrollment target
NCT01852136 is a clinical trial that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 217 participants.
The verdict
NCT01852136 has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 217 participants
- Enrollment target
Study Summary
This prospective, multi-center, 2 period cross-over study is designed to determine if people who use injection pens for subcutaneous medication delivery prefer the BD NEXT pen needle (PN) in comparison with currently marketed pen needles of the same or similar gauge and length. Subjects will use the investigational (BD NEXT) PN and their usual conventional PN each for one week in a randomly assigned sequence, and will be asked to evaluate and compare characteristics of the BD NEXT pen needle versus their usual pen needle when used for all their pen injections performed at home. Since injection experience may vary according to the type of pen device used, equal numbers of subjects will be recruited who are users of three of the most commonly used insulin pen injectors.
Interventions
- DEVICE BD NEXT 31G x 5 mm pen needle
- DEVICE BD NEXT 31G x 8mm pen needle
- DEVICE BD NEXT 32G x 4mm pen needle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2012-09 |
| Est. Completion | 2012-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01852136
The ClinicalTrials.gov registry entry for NCT01852136 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Becton, Dickinson and Company, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BD NEXT 31G x 5 mm pen needle is the first listed.
NCT01852136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01852136 about?
NCT01852136 is a clinical study titled "Clinical Evaluation of BD NEXT Pen Needle". This prospective, multi-center, 2 period cross-over study is designed to determine if people who use injection pens for subcutaneous medication delivery prefer the BD NEXT pen needle (PN) in comparison with currently marketed pen needles of the same or similar gauge and length. Subjects will use the...
What is the current status of trial NCT01852136?
This trial is currently completed. The enrollment target is 217 participants. The study started on 2012-09. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01852136?
The interventions under investigation include: BD NEXT 31G x 5 mm pen needle (DEVICE), BD NEXT 31G x 8mm pen needle (DEVICE), BD NEXT 32G x 4mm pen needle (DEVICE).
Who is sponsoring clinical trial NCT01852136?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.